Association of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases

American Journal of Gastroenterology

Volumn 95, Issue 3, 2000, Pages 659-669

  Fallone, Carlo A ^c   Barkun, Alan N ^c   Göttke, Markus U ^a   Best, Linda M ^b   Loo, Vivian G ^c   Veldhuyzen Van Zanten, Sander ^b   Nguyen, Thanh ^a,b   Lowe, Aviva ^a,b   Fainsilber, Toby ^a,b   Kouri, Kim ^a   Beech, Robin ^a  

^a MCGILL UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRULENCE FACTOR;

ADULT; AGED; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; CONTROLLED STUDY; DUODENUM ULCER; DYSPEPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROSCOPY; GENE AMPLIFICATION; GENOTYPE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STOMACH CANCER; STOMACH ULCER; UPPER GASTROINTESTINAL TRACT;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; GENE EXPRESSION REGULATION, BACTERIAL; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 17644434620     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)00762-0     Document Type: Article

References (76)

1. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 1997;113(suppl):S4-8.
2. International Agency for Research of Cancer Monographs on the Evaluation of Carcinogenic Risks to Humans. Infection with Helicobacter pylori, volume 61. Lyon: IARC, 1994:177-240.
3. Parsonnet J., Friedman G.D., Daniel M.S., et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 325:1991;1127-1131.
4. Zucca E., Bertoni F., Roggero E., et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med. 338:1998;804-810.
5. Talley N.J., Hunt R.H. What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology. 113:(suppl):1997;S67-S77.
6. Sipponen P., Varis K., Fraki O., et al. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. Scand J Gastroenterol. 25:1990;966-973.
7. Cullen D.J.E., Collins B.J., Christiansen K.J., et al. Long term risk of peptic ulcer disease in people with Helicobacter pylori infection - A community based study. Gastroenterology. 104:1993;A60.
8. Megraud F., Brassens-Rabbe M.P., Denis F., et al. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol. 27:1989;1870-1873.
9. Labenz J., Blum A.L., Bayerdorffer E., et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 112:1997;1442-1447.
10. Friedman G., Fallone C.A., Mayrand S., et al. Is Helicobacter pylori eradication associated with the endoscopic development of esophagitis? Gastroenterology. 114:1998;A124.
11. Hawkey C.J., Tulassay Z., Szczepanski L., et al. Randomized controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention . Lancet. 352:1998;1016-1021.
12. Talley N.J., Colin-Jones D., Koch K.L., et al. Functional dyspepsia A classification with guidelines for diagnosis and management . Gastroenterol Int. 4:1991;145-160.
13. Talley N.J. Dyspepsia and heartburn A clinical challenge . Aliment Pharmacol Ther. 11:(suppl 2):1997;1-8.
14. Marshall B.J. Helicobacter pylori. Am J Gastroenterol. 89:(suppl):1994;S116-S128.
15. Fallone C.A., Mitchell A., Paterson W.G. Determination of the test performance of less costly methods of Helicobacter pylori detection. Clin Invest Med. 18:1995;177-185.
16. Loo V.G., Fallone C.A., De Souza E., et al. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. J Antimicrob Chemother. 40:1997;881-883.
17. Fallone C.A., Loo V.G., Lough J., et al. Hematoxylin and eosin staining of gastric tissue for the detection of Helicobacter pylori. Helicobacter. 2:1997;32-35.
18. Mullis K, Faloona F, Scharf S, et al. Specific enzymatic amplification of DNA in vitro: The polymerase chain reaction. Cold Spring Harbor Symposia on Quantitative Biology 1986;51:263-73.
19. Censini S., Lange C., Xiang Z., et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA. 93:1996;14648-14653.
20. Cover T.L., Tummuru M.K., Cao P., et al. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains. J Biolog Chem. 269:1994;10566-10573.
21. Atherton J.C., Cao P., Peek R.M. Jr, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori Association of specific vacA types with cytotoxin production and peptic ulceration . J Biol Chem. 270:1995;17771-17777.
22. Best L.M., Veldhuyzen van Zanten S.J., Bezanson G.S., et al. Serological detection of Helicobacter pylori by a flow microsphere immunofluorescence assay. J Clin Microbiol. 30:1992;2311-2317.
23. Best L.M., Veldhuyzen van Zanten S.J., Sherman P.M., et al. Serological detection of Helicobacter pylori antibodies in children and their parents. J Clin Microbiol. 32:1994;1193-1196.
24. Best L.M., Veldhuyzen van Zanten S.J. Detection of antibodies to H. pyloric cagA protein by flow cytometric immunoassay. Gut. 39:(suppl 2):1996;A120.
25. Veldhuyzen van Zanten S.J.O. Helicobacter pylori and non-ulcer dyspepsia - A critical look. Hunt R.H., Tytgat G.N.J. Helicobacter pylori. Basic mechanisms to clinical cure. 1998;235-244 Kluwer Academic Publishers, Dordrecht.
26. Wiener G.J., Morgan T.M., Copper J.B., et al. Ambulatory 24-hour eophageal ph monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci. 33:1988;1127-1133.
27. Smout A.J.P.M. Ambulatory monitoring of esophageal pH and pressure. Castell D.O. The esophagus. 2nd ed. 1995;153-166 Little, Brown and Company, New York.
28. Murphy D.W., Yuan Y., Castell D.O. Does the intraesophageal pH probe accurately detect acid reflux? Simultaneous recording with two pH probes in humans. Dig Dis Sci. 34:1989;649-656.
29. Jyotheeswaran S., Evans H., Shah A., et al. Prevalence of Helicobacter pylori in peptic ulcer patients in Greater Rochester, NY Is empirical triple therapy justified? Gastroenterology. 110:1996;A147.
30. Laine L., Hopkins R.J., Girardi L.S. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol. 93:1998;1409-1415.
31. Hansson L.R., Engstrand L., Nyren O., et al. Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology. 109:1995;885-888.
32. Parsonnet J. Lessons from the epidemiology of Helicobacter pylori and cancer. Hunt R.H., Tytgat G.N.J. Helicobacter pylori Basics mechanism to clinical cure 1996 . 1996;238-244 Kluwer Academic Publishers, Boston.
33. Graham D.Y. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer A model . Gastroenterology. 113:1997;1983-1991.
34. Beech R.N., Goettke M., Groody J.M., et al. Utility of vacA DNA as a genetic marker for virulence in Helicobacter pylori. Gastroenterology. 110:1996;A63.
35. Suerbaum S., Smith J.M., Bapumia K., et al. Free recombination within Helicobacter pylori. Proc Natl Acad Sci USA. 95:1998;12619-12624.
36. Atherton J.C., Peek R.M. Jr, Thamk T., et al. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology. 112:1997;92-99.
37. Fallone C.A., Barkun A.N., Göttke M.U., et al. A review of the possible bacterial determinants of clinical outcome in Helicobacter pylori infection. Can J Microbiol. 44:1998;201-210.
38. Navaglia F., Basso D., Piva M.G., et al. Helicobacter pylori cytotoxic genotype is associated with peptic ulcer and influences serology. Am J Gastroenterol. 93:1998;227-230.
39. Stephens J.C., Stewart J.A., Folwell A.M., et al. Helicobacter pylori cagA status, vacA genotypes and ulcer disease. Eur J Gastroenterol Hepatol. 10:1998;381-384.
40. Tummuru M.K., Sharma S.A., Blaser M.J. Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Mol Microbiol. 18:1995;867-876.
41. Takata T., Fujimoto S., Anzai K., et al. Analysis of the expression of CagA and VacA and the vacuolating activity in 167 isolates from patients with either peptic ulcers or non-ulcer dyspepsia. Am J Gastroenterol. 93:1998;30-34.
42. Orsini B., Ciancio G., Surrenti E., et al. Serologic detection of cagA positive Helicobacter pylori infection in a northern Italian population Its association with peptic ulcer disease . Helicobacter. 3:1998;15-20.
43. Cover T.L., Dooley C.P., Blaser M.J. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity. Infect Immun. 58:1990;603-610.
44. Crabtree J.E., Taylor J.D., Wyatt J.L., et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration and gastric pathology. Lancet. 338:1991;332-335.
45. Covacci A., Censini S., Bugnoli M., et al. Molecular characterization of the 128 kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA. 90:1993;5791-5795.
46. Weel J.F.L., van der Hulst R.W., Gerrits Y., et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis. 173:1996;1171-1175.
47. Ching C.K., Wong C.Y., Kwok E., et al. Prevalence of cagA-bering Helicobacter pylori strains detected by the anti-cagA assay in patients with peptic ulcer disease and in controls. Am J Gastroenterol. 91:1996;949-953.
48. Holtmann G., Talley N.J., Mitchell H., et al. Antibody response to specific H. pylori Antigens in functional dyspepsia, duodenal ulcer disease and health. Am J Gastroenterol. 93:1998;1222-1227.
49. Yang J.C., Wang T.H., Wang H.J., et al. Genetic analysis of the cytotoxin-associated gene and the vacuolating toxin gene in Helicobacter pylori strains isolated from Taiwanese patients. Am J Gastroenterol. 92:1997;1316-1321.
50. Shyu R.Y., Jiang S.Y., Lai C.H., et al. High frequency of cytotoxin-associated gene A in Helicobacter pylori isolated from asymptomatic subjects and peptic ulcer patients in Taiwan. J Clin Gastroenterol. 27:1998;54-59.
51. Maeda S., Kanai F., Ogura K., et al. High seropositivity of anti-cagA antibody in Helicobacter pylori-infected patients irrelevant to peptic ulcers and normal mucosa in Japan. Dig Dis Sci. 42:1997;1841-1847.
52. Pan Z.J., van der Hulst R.W., Feller M., et al. Equally high prevalences of infection with cagA-positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. J Clin Microbiol. 35:1997;1344-1347.
53. Owen R.J., Hurtado A., Benatvala N., et al. Conservation of the cytotoxin-associated (cagA) gene of Helicobacter pylori and investigation of association with vacuolating-cytotoxin activity and gastroduodenal disease. FEMS Immunol Med Microbiol. 9:1994;307-315.
54. Miehlke S., Kibler K., Kim J.G., et al. Allelic variation in the cagA gene of Helicobacter pylori obtained from Korea compared to the United States. Am J Gastroenterol. 91:1996;1322-1325.
55. Go M.F., Graham D.Y. Prevalence of the cagA gene in the majority of Helicobacter pylori strains is independent of whether the individual has duodenal ulcer or asymptomatic gastritis. Helicobacter. 1:1996;107-111.
56. Yamaoka Y., El-Zimaity H.M.T., Gutierrez O., et al. Relationship between the cagA 3′ repeat region of Helicobacter pylori, gastric histology and susceptibility to low pH. Gastroenterology. 117:1999;342-349.
57. Armstrong D, Hunt RH. Helicobacter pylori and dyspepsia: a conceptual approach. In: Hunt RH, Tytgat GNJ, eds, Helicobacter pylori: Basics mechanism to clinical cure 1996. Boston: Kluwer Academic Publishers, 1996:324-39.
58. Talley N.J., Hunt R.H. What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology. 113:(suppl 6):1997;S67-S77.
59. Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol. 31:(suppl 215):1996;38-47.
60. El-Serag H.B., Sonnenberg A., Jamal M.M., et al. Corpus gastritis is protective against reflux oesophagitis. Gut. 45:1999;181-185.
61. Peek R.M., Miller G.G., Tham K.T., et al. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest. 71:1995;760-770.
62. Feldman M., Cryer B., McArthur K.E., et al. Relationship between severity of H. pylori (Hp) gastritis and gastric acid-pepsin secretion in man. Gastroenterology. 110:1996;A106.
63. Jaup B. Gastroesophageal reflux after cure of H. pylori infection. Gastroenterology. 113:1997;2019.
64. El-Omar E., Oien K., Wirz A., et al. Divergent effects of H. pylori on acid secretion. Gastroenterology. 110:1996;A102.
65. El-Omar E., Oien K., Nujuni A.E., et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 113:1997;15-24.
66. Bercík P., Verdú E.F., Armstrong D., et al. H. pylori related increase in omeprazole (ome) effect is associated with ammonia production. Gastroenterology. 110:1996;A64.
67. Bercík P., Verdú E.F., Armstrong D., et al. Apparent increase in acid output during omeprazole after cure of H. pylori infection. Gastroenterology. 112:1997;A70.
68. Vicari J.J., Peek R.M., Falk G.W., et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology. 115:1998;50-57.
69. Ödman B., Lindberg G., Befrits R., et al. Gastro-oesophageal reflux in duodenal ulcer patients after treatment for H. pylori during a two-year follow-up. Gut. 43:(suppl 2):1998;A99.
70. Malfertheiner P., Veldhuyzen van Zanten S., Dent J., et al. Does cure of Helicobacter pylori infection induce heartburn? Gastroenterology. 114:1998;A212.
71. Werdmuller B.F., Loffeld R.J. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci. 42:1997;103-105.
72. Wu J.C.Y., Go M.Y.Y., Chan W.B., et al. Prevalence and distribution of H. pylori in gastro-esophageal reflux disease A study in Chinese . Gastroenterology. 114:1998;A334.
73. Csendes A., Smok G., Cerda G., et al. Prevalence of Helicobacter pylori in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis Esophagus. 10:1997;38-42.
74. Vicari J.J., Falk G.W., Vaezi M.F., et al. CagA positivity may be protective against more severe grades of esophagitis. Gastroenterology. 114:1998;A324.
75. Vaezi M.F., Vicari J.J., Falk G.W., et al. CagA+ H. pylori colonization may prevent barrett's esophagus. Gastroenterology. 114:1998;A316.
76. Chow W.H., Blaser M.J., Blot W.J., et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 58:1998;588-590.